Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | AR | P10275 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3435588 | 0.81 | HDAC1 (0.40) | SIRT2SIRT1 | |
| SCHEMBL4513293 | 0.81 | MAPK1 (0.41) | SIRT2SIRT1ALDH1A1LMNAGAA | |
| SCHEMBL3436312 | 0.80 | SIRT1 (0.40) | SIRT2SIRT1ALDH1A1MAPTAR | |
| SCHEMBL3436233 | 0.80 | SLC6A9 (0.49) | SIRT2SIRT1ALDH1A1LMNAHTT | |
| SCHEMBL3434159 | 0.80 | SLC6A9 (0.49) | SIRT2SIRT1ALDH1A1LMNAHTT | |
| SCHEMBL9142677 | 0.77 | CHRNA7 (0.45) | ALDH1A1LMNAHTTKMT2A | |
| SCHEMBL9142672 | 0.77 | CHRNA7 (0.45) | ALDH1A1LMNAHTTKMT2A | |
| SCHEMBL9142665 | 0.77 | CHRNA7 (0.45) | ALDH1A1LMNAHTTKMT2A | |
| SCHEMBL3435994 | 0.71 | HTR1A (0.53) | SIRT2SIRT1ALDH1A1LMNAGAA | |
| SCHEMBL29772882 | 0.70 | MAPT (0.44) | ALDH1A1LMNAGAAMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | SIRT2 529/4885SIRT1 225/4885ALDH1A1 975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.